Webinar | Hep C Testing and Pre-Treatment Evaluation @HepCure
October 20 @ 4:30 pm - 5:30 pm EDT
HepCure/CEI Tele-Education Webinar Series Presents:
Hepatitis C Testing and
Date: October 20, 2020
Time: 4:30 – 5:30 PM EST
* Pre-registration for this free session is required
CE credits can only be claimed if you pre-register for this webinar
1. Click HERE to register
2. Fill out the short registration form
3. You will receive a confirmation email with the zoom login information
1. Define sustained virologic response (SVR).2. Describe how to manage cirrhotic patients post SVR.
3. Discuss at-risk populations for HCV reinfection.
Jennifer Price, MD, PhD
Associate Professor of Medicine
Director, Viral Hepatitis Center
Division of Gastroenterology/Liver Transplant
University of California San Francisco
About Dr. Price
Jennifer Price, MD, PhD is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and Director of the UCSF Viral Hepatitis Center. Her research examines the contributions of novel and traditional factors associated with liver disease and fibrosis progression in large observational HIV cohorts, with or without viral hepatitis. Dr. Price is a PI of the San Francisco Bay Area site of the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), which integrates two of the largest and longest-running NIH-funded prospective cohorts of men and women with and at risk for HIV in the U.S. She also serves as co-Chair of the MWCCS Liver Working Group and Vice Chair of the AASLD HCV SIG. Dr. Price is a member of the End Hep C SF Coordinating Committee and leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She is the founding director of the DeLIVER Care Van, a mobile unit aimed at improving access to HCV screening and high-quality liver-related health care among marginalized communities.